CAJ | 학술논문

目的：探讨重组人血管内皮抑制素（恩度）联合化疗一线治疗晚期转移性结直肠癌的疗效及安全性。方法：60例晚期转移性结直肠癌分为试验组（ n＝30）和对照组（ n＝30），对照组采用FOLFOX4化疗方案，试验组采用恩度联合FOLFOX4方案。结果：试验组和对照组获得的有效率（ RR）分别为53.3％和36.7％（ P<0.05），疾病控制率（DCR）为83.3％和73.3％（P<0.05），两组患者的中位无进展生存期（PFS）分别为7.3个月和5.3个月（P<0.05），中位总生存时间（OS）分别为11.6个月和9.3个月（P<0.05）。对其中的27例肝转移患者进行亚组分析，试验组和对照组RR及DCR比较差异均有统计学意义（ P<0.05），但是PFS及OS无统计学意义（ P>0.05）。主要不良反应为血液学毒性、消化道反应、神经毒性等，多为I-II级。两组患者经化疗后QOL均得到较大程度的改善；与治疗前相比，治疗后CEA和CA199均显著下降，且治疗后试验组下降较对照组更明显（ P<0.05）。结论：恩度联合化疗一线治疗晚期转移性结直肠癌安全有效。
목적：탐토중조인혈관내피억제소（은도）연합화료일선치료만기전이성결직장암적료효급안전성。방법：60례만기전이성결직장암분위시험조（ n＝30）화대조조（ n＝30），대조조채용FOLFOX4화료방안，시험조채용은도연합FOLFOX4방안。결과：시험조화대조조획득적유효솔（ RR）분별위53.3％화36.7％（ P<0.05），질병공제솔（DCR）위83.3％화73.3％（P<0.05），량조환자적중위무진전생존기（PFS）분별위7.3개월화5.3개월（P<0.05），중위총생존시간（OS）분별위11.6개월화9.3개월（P<0.05）。대기중적27례간전이환자진행아조분석，시험조화대조조RR급DCR비교차이균유통계학의의（ P<0.05），단시PFS급OS무통계학의의（ P>0.05）。주요불량반응위혈액학독성、소화도반응、신경독성등，다위I-II급。량조환자경화료후QOL균득도교대정도적개선；여치료전상비，치료후CEA화CA199균현저하강，차치료후시험조하강교대조조경명현（ P<0.05）。결론：은도연합화료일선치료만기전이성결직장암안전유효。
Objective:To analyze the efficacy and safety of Rh-endostatin( endostar)combined with chemothera-py in the treatment of metastatic colorectal cancer. Methods:All 60 metastatic colorectal cancer patients were divided into the test group(n=30)and the control group(n=30). The control group was treated with chemotherapy regimen FOLFOX4,the test group was treated by Endostar combined with FOLFOX4 scheme. Results:The response rates were 53. 3% in test group and 36. 7% in control group respectively(P<0. 05),the disease control rate were 83. 3% and 73. 3%(P<0. 05). The median progression -free survival in test group and control group were 7. 3 months ver-sus 5. 3 months(P<0. 05)and median overall survival were 11. 6 months versus 9. 3 months(P<0. 05). Among 27 cases of liver metastases were sub group analysis,difference on the test group and the control group RR and DCR had statistical significance(P<0. 05),but difference on PFS and OS had no statistical significance(P>0. 05). The major toxicities were myelosuppression,gastrointestinal symptoms,neurotoxicity,most in grade I -II. After chemotherapy, QOL of patients were more improved than before treatment. After treatment the CEA and CA199 levels decreased obvi-ously,furtheremore,the test group decreased more obviously than the control group. Conclusion:Rh-endostatin com-bined with chemotherapy in the treatment of metastatic colorectal cancer is safe and effective,and also improves pro-gression-free survival.